SEC 13F Intelligence

Royce & Associates LP / HAE

Royce & Associates LP’s Haemonetics Corp Mass Position

Does Royce & Associates LP own Haemonetics Corp Mass (HAE)? Yes — 71.5K shares worth $4M (+0.04% of its 13F portfolio) as of Q1 2026.

Position Value
$4M
Q1 2026
Shares
71.5K
% of Portfolio
+0.04%
Quarters Held
26
currently held

Position History HAE

Reported value by quarter
Q4 ’19: $3MQ4 ’19Q1 ’20: $38MQ2 ’20: $44MQ3 ’20: $51MQ4 ’20: $71MQ4 ’20Q1 ’21: $52MQ2 ’21: $40MQ3 ’21: $69MQ4 ’21: $38MQ4 ’21Q1 ’22: $48MQ2 ’22: $55MQ3 ’22: $65MQ4 ’22: $64,923Q4 ’22Q1 ’23: $70MQ2 ’23: $77MQ3 ’23: $85MQ4 ’23: $83MQ4 ’23Q1 ’24: $108MQ2 ’24: $98MQ3 ’24: $97MQ4 ’24: $90MQ4 ’24Q1 ’25: $74MQ2 ’25: $95MQ3 ’25: $34MQ4 ’25: $6MQ4 ’25Q1 ’26: $4Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 202671.5K$4M+0.04%
Q4 202571.5K$6M+0.06%
Q3 2025701.2K$34M+0.34%
Q2 20251.27M$95M+0.97%
Q1 20251.16M$74M+0.80%
Q4 20241.15M$90M+0.84%
Q3 20241.21M$97M+0.88%
Q2 20241.18M$98M+0.91%
Q1 20241.27M$108M+0.96%
Q4 2023966.4K$83M+0.76%
Q3 2023947.5K$85M+0.86%
Q2 2023906.3K$77M+0.75%
Q1 2023843.8K$70M+0.70%
Q4 2022825.5K$64,923+0.68%
Q3 2022874.8K$65M+0.73%
Q2 2022841.6K$55M+0.56%
Q1 2022757.2K$48M+0.41%
Q4 2021708.1K$38M+0.28%
Q3 2021984.4K$69M+0.52%
Q2 2021601.5K$40M+0.28%
Q1 2021468.6K$52M+0.35%
Q4 2020598.8K$71M+0.59%
Q3 2020583.6K$51M+0.55%
Q2 2020493.2K$44M+0.49%
Q1 2020376.6K$38M+0.51%
Q4 201930.2K$3M+0.03%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Royce & Associates LP’s full portfolio or all institutional holders of HAE.